Predicting memapsin 2 (β-secretase) hydrolytic activity
Xiaoman Li1, Huang Bo, Xuejun C Zhang
1Protein Studies Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma 73104, USA.
Abstract:
Memapsin 2 (BACE1, β-secretase), a membrane aspartic protease, functions in the cleavage of brain β-amyloid precursor protein (APP) leading to the production of β-amyloid. Because the excess level of β-amyloid in the brain is a leading factor in Alzheimer's disease (AD), memapsin 2 is a major therapeutic target for inhibitor drugs. The substrate-binding cleft of memapsin 2 accommodates 12 subsite residues, from P(8) to P(4)'. We have determined the hydrolytic preference as relative k(cat)/K(M) (preference constant) in all 12 subsites and used these data to establish a predictive algorithm for substrate hydrolytic efficiency. Using the sequences from 12 reported memapsin 2 protein substrates, the predicted and experimentally determined preference constants have an excellent correlation coefficient of 0.97. The predictive model indicates that the hydrolytic preference of memapsin 2 is determined mainly by the interaction with six subsites (from P(4) to P(2)'), a conclusion supported by the crystal structure B-factors calculated for the various residues of transition-state analogs bound to different memapsin 2 subsites. The algorithm also predicted that the replacement of the P(3), P(2), and P(1) subsites of APP from Val, Lys, and Met, respectively, to Ile, Asp, and Phe, respectively, (APP(IDF)) would result in a highest hydrolytic rate for β-amyloid-generating APP variants. Because more β-amyloid was produced from cells expressing APP(IDF) than those expressing APP with Swedish mutations, this designed APP variant may be useful in new memapsin 2 substrates or transgenic mice for AD studies.
Insights
Memapsin 2 (BACE1) enzyme activity was predicted using a novel algorithm based on substrate-binding cleft preferences. This algorithm accurately forecasts enzyme efficiency and identifies new therapeutic targets for Alzheimer's disease.
Area of Science:
- Biochemistry
- Enzymology
- Neuroscience
Background:
- Memapsin 2 (BACE1) cleaves amyloid precursor protein (APP), producing β-amyloid, a key factor in Alzheimer's disease (AD).
- BACE1 is a primary therapeutic target for AD inhibitor drugs due to its role in β-amyloid production.
Purpose of the Study:
- To determine the hydrolytic preference of memapsin 2 across its 12 substrate-binding subsites.
- To develop a predictive algorithm for memapsin 2 substrate hydrolytic efficiency.
- To identify modified APP variants with potentially higher BACE1 cleavage rates.
Main Methods:
- Determined relative k(cat)/K(M) (preference constant) for all 12 memapsin 2 subsites.
- Developed a predictive algorithm using substrate sequences and experimentally determined preference constants.
- Validated the algorithm against 12 known memapsin 2 protein substrates.
- Analyzed crystal structure B-factors of bound transition-state analogs.
Main Results:
- Established a predictive algorithm with an excellent correlation coefficient of 0.97 between predicted and experimental preference constants.
- Identified six key subsites (P(4) to P(2)') that primarily determine memapsin 2 hydrolytic preference.
- Predicted that an APP variant (APP(IDF)) with specific amino acid substitutions would exhibit the highest hydrolytic rate.
Conclusions:
- The developed algorithm accurately predicts memapsin 2 substrate cleavage efficiency.
- The P(4) to P(2)' subsites are critical for memapsin 2 substrate recognition and hydrolysis.
- The designed APP(IDF) variant shows promise for use in AD research models, potentially enhancing β-amyloid production studies.
More Related Videos
11:04Ion Mobility-Mass Spectrometry Techniques for Determining the Structure and Mechanisms of Metal Ion Recognition and Redox Activity of Metal Binding Oligopeptides
Published on: September 7, 2019
06:40Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms
Published on: January 25, 2018
